MRES (Institute of Biomedical Research) ROE %: 0.00% (As of Dec. 2010)


What is Institute of Biomedical Research ROE %?

Institute of Biomedical Research MRES ROE % is 0.00% as of Dec. 2010.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Institute of Biomedical Research's annualized net income for the quarter that ended in Dec. 2010 was $-0.22 Mil. Institute of Biomedical Research's average Total Stockholders Equity over the quarter that ended in Dec. 2010 was $-0.40 Mil. Therefore, Institute of Biomedical Research's annualized ROE % for the quarter that ended in Dec. 2010 was N/A%.

The historical rank and industry rank for Institute of Biomedical Research's ROE % or its related term are showing as below:

MRES's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.18
* Ranked among companies with meaningful ROE % only.

Institute of Biomedical Research  (OTCPK:MRES) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2010 )
=Net Income/Total Stockholders Equity
=-0.224/-0.3965
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.224 / 0)*(0 / 0.6615)*(0.6615 / -0.3965)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2010 )
=Net Income/Total Stockholders Equity
=-0.224/-0.3965
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.224 / -0.224) * (-0.224 / -0.072) * (-0.072 / 0) * (0 / 0.6615) * (0.6615 / -0.3965)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 3.1111 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2010) net income data. The Revenue data used here is four times the quarterly (Dec. 2010) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Institute of Biomedical Research ROE % Related Terms


Institute of Biomedical Research ROE % Historical Data

* Premium members only.

The historical data trend for Institute of Biomedical Research's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Institute of Biomedical Research ROE % Chart

Institute of Biomedical Research Annual Data
Trend Dec03 Dec04 Mar06 Mar07 Mar08 Mar09 Mar10
ROE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Institute of Biomedical Research Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MRES vs HSTC, NTRR, VITIF: ROE % Comparison

For the Biotechnology subindustry, Institute of Biomedical Research's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Institute of Biomedical Research ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Institute of Biomedical Research's ROE % distribution charts can be found below:

* The bar in red indicates where Institute of Biomedical Research's ROE % falls into.



Institute of Biomedical Research ROE % Calculation

Institute of Biomedical Research's annualized ROE % for the fiscal year that ended in Mar. 2010 is calculated as

ROE %=Net Income (A: Mar. 2010 )/( (Total Stockholders Equity (A: Mar. 2009 )+Total Stockholders Equity (A: Mar. 2010 ))/ count )
=-0.273/( (-0.072+-0.345)/ 2 )
=-0.273/-0.2085
=N/A %

Institute of Biomedical Research's annualized ROE % for the quarter that ended in Dec. 2010 is calculated as

ROE %=Net Income (Q: Dec. 2010 )/( (Total Stockholders Equity (Q: Sep. 2010 )+Total Stockholders Equity (Q: Dec. 2010 ))/ count )
=-0.224/( (-0.986+0.193)/ 2 )
=-0.224/-0.3965
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2010) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Institute of Biomedical Research (MRES) has a ROE % of 0.00% as of Dec. 2010. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Institute of Biomedical Research and its competitors.
Is Institute of Biomedical Research's ROE % too high?
Institute of Biomedical Research's current ROE % is 0.00%.
How does Institute of Biomedical Research's ROE % compare to HSTC and NTRR?
Institute of Biomedical Research's ROE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Institute of Biomedical Research and its competitors. Institute of Biomedical Research's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Institute of Biomedical Research stock overvalued right now?
Institute of Biomedical Research (MRES) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Institute of Biomedical Research (MRES), the current ROE % is 0.00% as of Dec. 2010. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Institute of Biomedical Research Business Description

Address Dubai Science Park, 13th Floor, South Tower, Dubai, ARE, 416452
Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based food and medicine and mental health therapeutic research. The company uses brand name M2Bio Sciences engaged in deploying artificial intelligence, science and medicine, clinical research, and emerging technologies.